


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:51Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406652" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406652</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>aac</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406652</article-id><article-id pub-id-type="pmcid-ver">PMC12406652.1</article-id><article-id pub-id-type="pmcaid">12406652</article-id><article-id pub-id-type="pmcaiid">12406652</article-id><article-id pub-id-type="pmid">40762486</article-id><article-id pub-id-type="doi">10.1128/aac.00210-25</article-id><article-id pub-id-type="publisher-id">aac00210-25</article-id><article-id pub-id-type="publisher-id">aac.00210-25</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Therapeutics</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-4989-4896</contrib-id><name name-style="western"><surname>de Oliveira</surname><given-names initials="CF">Carlos Fernando</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dorr</surname><given-names initials="MB">Mary Beth</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>van de Wetering</surname><given-names initials="J">Jeroen</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lowe</surname><given-names initials="K">Kathryn</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sabato</surname><given-names initials="P">Philip</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Winchell</surname><given-names initials="G">Gregory</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="H">Hongzi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5906-2818</contrib-id><name name-style="western"><surname>McGovern</surname><given-names initials="PC">Paul C.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role><email>mcgovern@venatorx.com</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Venatorx Pharmaceuticals, Inc.</institution></institution-wrap>, <city>Malvern</city>, <state>Pennsylvania</state>, <country>USA</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>PRA Health Sciences</institution></institution-wrap>, <city>Groningen</city>, <country>the Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>Winchell Pharma Consulting, LLC</institution><institution-id institution-id-type="ringgold">509759</institution-id></institution-wrap>, <city>Norristown</city>, <state>Pennsylvania</state>, <country>USA</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Doernberg</surname><given-names initials="S">Sarah</given-names></name><aff><institution-wrap><institution>University of California San Francisco</institution></institution-wrap>, <city>San Francisco</city>, <state>California</state>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Paul C. McGovern, <email xlink:href="mailto:mcgovern@venatorx.com">mcgovern@venatorx.com</email></corresp><fn fn-type="COI-statement"><p>K.L. and P.C.M. are employees of Venatorx Pharmaceuticals, Inc., Malvern, PA. M.B.D., C.F.O., P.S., and H.C. were employees of Venatorx Pharmaceuticals, Inc., at the time this work was conducted. G.W. is principal of Winchell Pharma Consulting, LLC, and performed work as a paid contractor for Venatorx Pharmaceuticals, Inc. J.W. is an employee of ICON plc (formerly PRA Health Sciences).</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>9</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>8</month><year>2025</year></pub-date><volume>69</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496152</issue-id><elocation-id>e00210-25</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 de Oliveira et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>de Oliveira et al.</copyright-holder><ali:free_to_read start_date="2025-08-05"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="aac.00210-25.pdf"/><self-uri content-type="pdf" xlink:href="aac.00210-25.pdf"/><related-article related-article-type="companion" xml:lang="en" xlink:title="research-article" journal-id="Antimicrob Agents Chemother" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12406654"><article-title>Pharmacokinetics and safety of single and repeat doses of ceftibuten in healthy participants: a phase 1 dose escalation study</article-title><volume>69</volume><issue>9</issue><date><day>5</day><month>8</month><year>2025</year></date><elocation-id>e00087-25</elocation-id><source>Antimicrobial Agents and Chemotherapy</source><pub-id pub-id-type="doi">10.1128/aac.00087-25</pub-id><pub-id pub-id-type="pmcid">PMC12406654</pub-id><pub-id pub-id-type="pmid">40762485</pub-id></related-article><abstract abstract-type="primary"><title>ABSTRACT</title><p>Ledaborbactam etzadroxil (LED-E), a novel oral prodrug that converts to the active &#946;-lactamase inhibitor (BLI) ledaborbactam (LED), is being developed in combination with ceftibuten (CTB) to address a need for oral treatments against drug-resistant Enterobacterales infections. Two Phase 1 studies were conducted to (i) evaluate the safety and pharmacokinetics of single doses of LED-E 100 to 1000 mg and multiple doses of LED-E 75 to 500 mg every 8 h (q8h) for 10 days, (ii) assess potential drug interactions between CTB and LED, and (iii) evaluate safety and pharmacokinetics following multiple doses of LED-E 300 or 500 mg with CTB 400 mg or placebo q8h for 10 days. Treatment-emergent adverse events (TEAEs) were reported for 82% LED-E &#177; CTB (<italic toggle="yes">n</italic> = 109) and 78% placebo (<italic toggle="yes">n</italic>=27) participants, respectively. TEAEs of gastrointestinal disorders were reported for 28% of the LED-E &#177; CTB and 15% of placebo participants. Following single doses, LED-E AUC<sub>inf</sub> was less than 2% of LED exposures, demonstrating extensive conversion to active BLI. LED AUC increased dose proportionally following single LED doses and less than proportionally following multiple LED-E doses. After 10 days of q8h dosing, the LED terminal half-life in plasma was approximately 11 to 12 h. Steady-state urinary excretion of LED-E&#8211;derived material (comprised almost entirely of unchanged LED) was 84%. No clinically relevant CTB and LED PK interactions occurred with the CTB + LED-E combination. These results support further development of the CTB + LED-E combination for the treatment of complicated urinary tract infections caused by drug-resistant Enterobacterales.</p><sec><title>CLINICAL TRIALS</title><p>These studies are registered with ClinicalTrials.gov as <related-object source-type="clinical-trials-registry" source-id-type="registry-name" source-id="ClinicalTrials.gov" document-id="NCT04243863" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/study/NCT04243863" id="RO1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04243863">NCT04243863</ext-link></related-object> and <related-object source-type="clinical-trials-registry" source-id-type="registry-name" source-id="ClinicalTrials.gov" document-id="NCT04877379" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/study/NCT04877379" id="RO2"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04877379">NCT04877379</ext-link></related-object>.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>ceftibuten</kwd><kwd>ledaborbactam</kwd><kwd>ledaborbactam etzadroxil</kwd><kwd>VNRX-7145</kwd><kwd>VNRX-5236</kwd><kwd>beta-lactamase inhibitor</kwd><kwd>drug safety</kwd><kwd>pharmacokinetics</kwd><kwd>first-in-human</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>National Institute of Allergy and Infectious Diseases</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id></institution-wrap></funding-source><award-id>HHSN272201600029C</award-id><principal-award-recipient><name name-style="western"><surname>de Oliveira</surname><given-names>Carlos Fernando</given-names></name><name name-style="western"><surname>Dorr</surname><given-names>Mary Beth</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>Kathryn</given-names></name><name name-style="western"><surname>Sabato</surname><given-names>Philip</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Hongzi</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>Paul C.</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><count count-type="authors" count="8"/><fig-count count="1"/><table-count count="4"/><equation-count count="0"/><ref-count count="15"/><page-count count="11"/><word-count count="6019"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Drug-resistant Gram-negative pathogens pose a critical public health threat (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Resistance has been demonstrated to nearly all antibiotic classes, including last-resort options, such as carbapenems and colistin (<xref rid="B3" ref-type="bibr">3</xref>). Rapid spread and acquisition of resistance genes leave fewer effective treatments, straining healthcare systems and increasing morbidity and mortality (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). This underscores the urgent need for new antibiotics to treat infections due to antimicrobial-resistant pathogens (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>).</p><p>Ledaborbactam etzadroxil (LED-E; formerly VNRX-7145) is an oral prodrug of ledaborbactam (LED; VNRX-5236), a novel broad-spectrum &#946;-lactamase inhibitor. Ceftibuten (CTB; Cedax), a broad-spectrum, third-generation oral cephalosporin, and LED-E represents a new &#946;-lactam/&#946;-lactamase inhibitor combination designed to address the urgent need for oral treatments effective against drug-resistant Gram-negative pathogens. CTB + LED-E restores CTB activity against Enterobacterales expressing challenging resistance mechanisms, including extended-spectrum &#946;-lactamases (ESBLs) and carbapenemases, such as KPC and OXA-48 (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Here, we describe results from two Phase 1 studies from the CTB + LED-E drug development program. The first-in-human study VNRX-7145-101 (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04243863">NCT04243863</ext-link>) focused on the safety and pharmacokinetics following single and multiple doses of LED-E in healthy participants. VNRX-7145-102 (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04877379">NCT04877379</ext-link>) expanded on this by evaluating the potential for drug-drug interactions between CTB and LED and the safety and pharmacokinetics of multiple doses of the CTB + LED-E combination in healthy participants.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Disposition and participant demographics</title><p>Across both studies, 136 participants (LED-E &#177; CTB, <italic toggle="yes">n</italic> = 109; placebo, <italic toggle="yes">n</italic> = 27) were enrolled and received at least one dose of study drug, and 132 participants completed all study procedures. One participant in the LED-E 150 mg every 8 h (q8h) group discontinued due to a TEAE; all other discontinuations were due to loss to follow-up or protocol noncompliance.</p><p><xref rid="SuF1" ref-type="supplementary-material">Table S1</xref> summarizes demographics and clinical characteristics at baseline for all participants. The mean age was 31.0 years (SD, 8.5 years; range, 18 to 53 years), 56.6% of participants were female, 70.6% were White, 17.6% were Black or African American, and 40.4% were Hispanic or Latino. The distribution of these characteristics was similar between the pooled LED-E &#177; CTB and placebo groups, except for the percentage of White patients, which was lower in the placebo group (59.3%) than in the CTB + LED-E (73.4%) group. The mean body mass index was 25.5 kg/m<sup>2</sup> (SD, 3.2 kg/m<sup>2</sup>; range, 18.9 to 31.9 kg/m<sup>2</sup>).</p></sec><sec id="s2-2"><title>Safety and tolerability</title><p>The numbers of participants with treatment-emergent AEs (TEAE) were similar in the LED-E &#177; CTB (81.7%) and placebo (77.8%) groups (<xref rid="T1" ref-type="table">Table 1</xref>). Among LED-E-dosed participants, headache (20.2%) and fatigue (9.2%) were the most frequently reported TEAEs. Gastrointestinal TEAEs occurred in 27.5% of LED-E-dosed participants and 14.8% of placebo-dosed participants, were all mild in severity, and did not lead to discontinuation of study drug. There was no dose relationship with the frequency or severity of TEAEs for gastrointestinal events.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Treatment-emergent adverse events in &#8805;2% of healthy participants who received ledaborbactam etzadroxil (LED-E) with or without ceftibuten (CTB) or placebo<xref rid="T1_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">TEAE<sup><xref rid="T1_FN2" ref-type="table-fn"><italic toggle="yes">b</italic></xref></sup></th><th align="left" valign="top" colspan="1" rowspan="1">LED-E &#177; CTB<sup><xref rid="T1_FN3" ref-type="table-fn"><italic toggle="yes">c</italic></xref></sup><break/>(<italic toggle="yes">n</italic> = 109)</th><th align="left" valign="top" colspan="1" rowspan="1">Placebo<break/>(<italic toggle="yes">n</italic> = 27)</th><th align="left" valign="top" colspan="1" rowspan="1">Total<break/>(<italic toggle="yes">N</italic> = 136)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Any TEAE</td><td align="left" valign="top" colspan="1" rowspan="1">89 (81.7)</td><td align="left" valign="top" colspan="1" rowspan="1">21 (77.8)</td><td align="left" valign="top" colspan="1" rowspan="1">110 (80.9)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Gastrointestinal disorders</td><td align="left" valign="top" colspan="1" rowspan="1">30 (27.5)</td><td align="left" valign="top" colspan="1" rowspan="1">4 (14.8)</td><td align="left" valign="top" colspan="1" rowspan="1">34 (25.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Abdominal pain</td><td align="left" valign="top" colspan="1" rowspan="1">9 (8.3)</td><td align="left" valign="top" colspan="1" rowspan="1">2 (7.4)</td><td align="left" valign="top" colspan="1" rowspan="1">11 (8.1)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Constipation</td><td align="left" valign="top" colspan="1" rowspan="1">4 (3.7)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">4 (2.9)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Frequent bowel movements</td><td align="left" valign="top" colspan="1" rowspan="1">7 (6.4)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">7 (5.1)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Nausea</td><td align="left" valign="top" colspan="1" rowspan="1">9 (8.3)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">9 (6.6)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">General disorders and administration site conditions</td><td align="left" valign="top" colspan="1" rowspan="1">23 (21.1)</td><td align="left" valign="top" colspan="1" rowspan="1">5 (18.5)</td><td align="left" valign="top" colspan="1" rowspan="1">28 (20.6)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Fatigue</td><td align="left" valign="top" colspan="1" rowspan="1">10 (9.2)</td><td align="left" valign="top" colspan="1" rowspan="1">1 (3.7)</td><td align="left" valign="top" colspan="1" rowspan="1">11 (8.1)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Nervous system disorders</td><td align="left" valign="top" colspan="1" rowspan="1">25 (22.9)</td><td align="left" valign="top" colspan="1" rowspan="1">4 (14.8)</td><td align="left" valign="top" colspan="1" rowspan="1">29 (21.3)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Dizziness</td><td align="left" valign="top" colspan="1" rowspan="1">5 (4.6)</td><td align="left" valign="top" colspan="1" rowspan="1">1 (3.7)</td><td align="left" valign="top" colspan="1" rowspan="1">6 (4.4)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Headache</td><td align="left" valign="top" colspan="1" rowspan="1">22 (20.2)</td><td align="left" valign="top" colspan="1" rowspan="1">2 (7.4)</td><td align="left" valign="top" colspan="1" rowspan="1">24 (17.6)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Somnolence</td><td align="left" valign="top" colspan="1" rowspan="1">4 (3.7)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">4 (2.9)</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Data include all participants from studies VNRX-7145-101 and VNRX-7145-102 who received &#8805;1 dose of study medication.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>TEAE, treatment-emergent adverse event. TEAEs were defined as adverse events with onset date-times on or after the date-times of first exposure to study treatments.</p></fn><fn id="T1_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>bCTB, ceftibuten; LED-E, ledaborbactam etzadroxil.</p></fn></table-wrap-foot></table-wrap><p>One participant in the LED-E 150 mg q8h group discontinued the study due to a mild, related TEAE of noncardiac chest pain. No serious adverse events or deaths occurred. No clinically relevant changes were noted in clinical laboratory values, ECGs, or vital signs.</p></sec><sec id="s2-3"><title>Pharmacokinetics</title><sec id="s2-3-1"><title>Single doses of LED-E</title><sec id="s2-3-1-1"><title>Plasma results</title><p>Pharmacokinetic parameters were assessed following a single dose of LED-E 100 to 1,000 mg. Arithmetic mean plasma concentration-time profiles for LED are shown in <xref rid="F1" ref-type="fig">Fig. 1A</xref>. LED concentrations increased rapidly after administration, reaching <italic toggle="yes">C</italic><sub>max</sub> at 1.25 to 2 h post-dose, then decreased in a biphasic manner over time. LED exposure generally increased dose proportionally, with geometric mean AUC<sub>inf</sub> values of 15.400 h&#183;&#181;g/mL (LED-E 100 mg) to 114.000 h&#183;&#181;g/mL (LED-E 1000 mg). LED <italic toggle="yes">C</italic><sub>max</sub> and AUC<sub>inf</sub> exhibited low variability across the dose range (<xref rid="T2" ref-type="table">Table 2</xref>).</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>Arithmetic mean plasma ledaborbactam concentrations following (<bold>A</bold>) single doses and (<bold>B</bold>) multiple doses (Day 10) of ledaborbactam etzadroxil. Primary figures show linear scale; insets show logarithmic scale.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00210-25.f001.jpg"><alt-text>Line graphs display ledaborbactam plasma concentrations over time after single and multiple oral doses. Insets depict same data on logarithmic scale, highlighting dose-dependent pharmacokinetics and greater exposure with higher doses.</alt-text></graphic></fig><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Plasma pharmacokinetic parameters for ledaborbactam and ledaborbactam etzadroxil, following single doses of ledaborbactam etzadroxil (LED-E)<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Parameter<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 100 mg<break/>(<italic toggle="yes">n</italic> = 6)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 200 mg<break/>(<italic toggle="yes">n</italic> = 6)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 300 mg<break/>(<italic toggle="yes">n</italic> = 6)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 500 mg<break/>(<italic toggle="yes">n</italic> = 6)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 800 mg<break/>(<italic toggle="yes">n</italic> = 6)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 1,000 mg<break/>(<italic toggle="yes">n</italic> = 6)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Ledaborbactam</td><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">T</italic><sub>max</sub>, h<sup><xref rid="T2_FN3" ref-type="table-fn"><italic toggle="yes">c</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1">1.25 (0.50&#8211;2.00)</td><td align="left" valign="top" colspan="1" rowspan="1">1.50 (1.00&#8211;3.00)</td><td align="left" valign="top" colspan="1" rowspan="1">1.25 (0.50&#8211;2.00)</td><td align="left" valign="top" colspan="1" rowspan="1">1.26 (1.00&#8211;3.00)</td><td align="left" valign="top" colspan="1" rowspan="1">2.00 (1.00&#8211;3.00)</td><td align="left" valign="top" colspan="1" rowspan="1">2.00 (1.00&#8211;3.00)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">4.010 (25.6)</td><td align="left" valign="top" colspan="1" rowspan="1">5.970 (11.8)</td><td align="left" valign="top" colspan="1" rowspan="1">7.570 (29.3)</td><td align="left" valign="top" colspan="1" rowspan="1">16.800 (8.43)</td><td align="left" valign="top" colspan="1" rowspan="1">24.000 (14.2)</td><td align="left" valign="top" colspan="1" rowspan="1">26.500 (7.92)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;AUC<sub>inf</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">15.400 (30.5)</td><td align="left" valign="top" colspan="1" rowspan="1">26.200 (16.7)</td><td align="left" valign="top" colspan="1" rowspan="1">33.100 (25.6)</td><td align="left" valign="top" colspan="1" rowspan="1">69.300 (15.2)</td><td align="left" valign="top" colspan="1" rowspan="1">125.000 (22.6)</td><td align="left" valign="top" colspan="1" rowspan="1">114.000 (8.82)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">t</italic><sub>1/2</sub>, h</td><td align="left" valign="top" colspan="1" rowspan="1">5.53 (18.7)</td><td align="left" valign="top" colspan="1" rowspan="1">6.10 (27.4)</td><td align="left" valign="top" colspan="1" rowspan="1">7.48 (32.4)</td><td align="left" valign="top" colspan="1" rowspan="1">11.3 (34.5)</td><td align="left" valign="top" colspan="1" rowspan="1">8.59 (42.9)</td><td align="left" valign="top" colspan="1" rowspan="1">11.3 (19.1)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Ledaborbactam etzadroxil</td><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">T</italic><sub>max</sub>, h<sup><xref rid="T2_FN3" ref-type="table-fn"><italic toggle="yes">c</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1">0.50 (0.50&#8211;1.00)</td><td align="left" valign="top" colspan="1" rowspan="1">0.50 (0.50&#8211;1.00)</td><td align="left" valign="top" colspan="1" rowspan="1">0.50 (0.50&#8211;1.50)</td><td align="left" valign="top" colspan="1" rowspan="1">0.51 (0.50&#8211;2.50)</td><td align="left" valign="top" colspan="1" rowspan="1">0.50 (0.50&#8211;1.50)</td><td align="left" valign="top" colspan="1" rowspan="1">0.75 (0.50&#8211;0.75)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">0.167 (79.7)</td><td align="left" valign="top" colspan="1" rowspan="1">0.167 (57.6)</td><td align="left" valign="top" colspan="1" rowspan="1">0.347 (95.5)</td><td align="left" valign="top" colspan="1" rowspan="1">0.917 (112)</td><td align="left" valign="top" colspan="1" rowspan="1">1.160 (95.3)</td><td align="left" valign="top" colspan="1" rowspan="1">1.840 (21.2)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;AUC<sub>inf</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">0.177 (53.4)</td><td align="left" valign="top" colspan="1" rowspan="1">0.249 (23.3)</td><td align="left" valign="top" colspan="1" rowspan="1">0.439 (52.7)</td><td align="left" valign="top" colspan="1" rowspan="1">1.290 (67.4)</td><td align="left" valign="top" colspan="1" rowspan="1">1.720 (68.0)</td><td align="left" valign="top" colspan="1" rowspan="1">2.300 (11.2)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">t</italic><sub>1/2</sub>, h</td><td align="left" valign="top" colspan="1" rowspan="1">2.81 (24.5)</td><td align="left" valign="top" colspan="1" rowspan="1">3.34 (6.35)</td><td align="left" valign="top" colspan="1" rowspan="1">3.63 (17.3)</td><td align="left" valign="top" colspan="1" rowspan="1">4.70 (13.3)</td><td align="left" valign="top" colspan="1" rowspan="1">3.37 (14.2)</td><td align="left" valign="top" colspan="1" rowspan="1">4.59 (7.73)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;CL/F, L/h</td><td align="left" valign="top" colspan="1" rowspan="1">564 (53.4)</td><td align="left" valign="top" colspan="1" rowspan="1">803 (23.3)</td><td align="left" valign="top" colspan="1" rowspan="1">683 (52.7)</td><td align="left" valign="top" colspan="1" rowspan="1">389 (67.4)</td><td align="left" valign="top" colspan="1" rowspan="1">465 (68.0)</td><td align="left" valign="top" colspan="1" rowspan="1">435 (11.2)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;V<sub>z</sub>/F, L</td><td align="left" valign="top" colspan="1" rowspan="1">2290 (50.7)</td><td align="left" valign="top" colspan="1" rowspan="1">3870 (22.2)</td><td align="left" valign="top" colspan="1" rowspan="1">3580 (62.9)</td><td align="left" valign="top" colspan="1" rowspan="1">2640 (62.6)</td><td align="left" valign="top" colspan="1" rowspan="1">2260 (68.7)</td><td align="left" valign="top" colspan="1" rowspan="1">2880 (15.1)</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Except where indicated, data are geometric mean (coefficient of variation, %). Data include participants from study VNRX-7145-101.</p></fn><fn id="T2_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>AUCinf, area under the concentration-time curve through infinity; CL/F, apparent total clearance; Cmax, maximum concentration; Tmax, time of maximum concentration; Vz/F, volume of distribution in the terminal phase.</p></fn><fn id="T2_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>Data are median hours (range).</p></fn></table-wrap-foot></table-wrap><p>Following single doses of LED-E 100 to 1,000 mg, the AUC<sub>inf</sub> of LED-E was &#8804;2% of LED exposures, suggesting extensive presystemic conversion of the prodrug to the active drug. Exposure (as measured by AUC) increased in a dose-proportional manner across the dose range, from a geometric mean AUC<sub>inf</sub> of 0.177 h&#183;&#181;g/mL (LED-E 100 mg) to 2.300 h&#183;&#181;g/mL (LED-E 1000 mg). Geometric mean plasma concentrations increased rapidly following single doses of LED-E with maximum plasma concentrations (<italic toggle="yes">C</italic><sub>max</sub>) reached 0.5 to 0.75 h post-dose (<xref rid="T2" ref-type="table">Table 2</xref>). The geometric mean <italic toggle="yes">t</italic><sub>1/2</sub> was 2.8 to 4.7 h, with no clear trend as dose increased.</p><p>Following coadministration with ceftibuten, an absence of an interaction for AUC<sub>inf</sub> was observed for LED (GMR, 0.99 [90% CI, 0.95 to 1.03]) ; LED-E AUC<sub>inf</sub> (GMR, 0.94 [0.85 to 1.04]); and cis-CTB (GMR, 0.88 [0.81 to 0.95]). For C<sub>max</sub>, an absence of interaction was demonstrated for LED (GMR, 0.96 [90% CI, 0.89 to 1.03]). For trans-CTB AUC<sub>inf</sub> (GMR, 0.86 [90% CI, 0.79 to 0.93]), LED-E <italic toggle="yes">C</italic><sub>max</sub> (GMR, 0.76 [90% CI, 0.66 to 0.87]), Cis-CTB <italic toggle="yes">C</italic><sub>max</sub> (GMR, 0.88 [0.79 to 0.97]), and trans-CTB <italic toggle="yes">C</italic><sub>max</sub> (GMR, 0.85 [90% CI, 0.77 to 0.94]), an interaction cannot be ruled out (<xref rid="T3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Summary of statistical analysis of potential drug-drug interactions following a single dose of ceftibuten (CTB) 400 mg + ledaborbactam etzadroxil (LED-E) 500 mg<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="3" colspan="1">Analyte</th><th align="left" valign="top" rowspan="3" colspan="1">Pharmacokinetic parameter (unit)<xref rid="T3_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref><sup>,<xref rid="T3_FN4" ref-type="table-fn"><italic toggle="yes">d</italic></xref></sup></th><th align="center" valign="top" colspan="2" rowspan="1">Geometric LS means<sup><xref rid="T3_FN2" ref-type="table-fn"><italic toggle="yes">b</italic></xref></sup></th><th align="center" valign="top" colspan="3" rowspan="1">Ratio of test/Reference</th></tr><tr><th align="left" valign="top" rowspan="2" colspan="1">Test</th><th align="left" valign="top" rowspan="2" colspan="1">Reference</th><th align="left" valign="top" rowspan="2" colspan="1">Estimate</th><th align="center" valign="top" colspan="2" rowspan="1">90% CI<sup><xref rid="T3_FN5" ref-type="table-fn"><italic toggle="yes">e</italic></xref></sup></th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1">Lower</th><th align="left" valign="top" colspan="1" rowspan="1">Upper</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2" colspan="1">Ledaborbactam<sup><xref rid="T3_FN6" ref-type="table-fn"><italic toggle="yes">f</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">13.16</td><td align="left" valign="top" colspan="1" rowspan="1">13.74</td><td align="left" valign="top" colspan="1" rowspan="1">0.96</td><td align="left" valign="top" colspan="1" rowspan="1">0.89</td><td align="left" valign="top" colspan="1" rowspan="1">1.03</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>inf</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">65.36</td><td align="left" valign="top" colspan="1" rowspan="1">66.30</td><td align="left" valign="top" colspan="1" rowspan="1">0.99</td><td align="left" valign="top" colspan="1" rowspan="1">0.95</td><td align="left" valign="top" colspan="1" rowspan="1">1.03</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Ledaborbactam etzadroxil<sup><xref rid="T3_FN6" ref-type="table-fn"><italic toggle="yes">f</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">0.787</td><td align="left" valign="top" colspan="1" rowspan="1">1.037</td><td align="left" valign="top" colspan="1" rowspan="1">0.76</td><td align="left" valign="top" colspan="1" rowspan="1">0.66</td><td align="left" valign="top" colspan="1" rowspan="1">0.87</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>inf</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">1.068</td><td align="left" valign="top" colspan="1" rowspan="1">1.138</td><td align="left" valign="top" colspan="1" rowspan="1">0.94</td><td align="left" valign="top" colspan="1" rowspan="1">0.85</td><td align="left" valign="top" colspan="1" rowspan="1">1.04</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Cis-ceftibuten<sup><xref rid="T3_FN7" ref-type="table-fn"><italic toggle="yes">g</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">15.41</td><td align="left" valign="top" colspan="1" rowspan="1">17.56</td><td align="left" valign="top" colspan="1" rowspan="1">0.88</td><td align="left" valign="top" colspan="1" rowspan="1">0.79</td><td align="left" valign="top" colspan="1" rowspan="1">0.97</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>inf</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">79.03</td><td align="left" valign="top" colspan="1" rowspan="1">90.09</td><td align="left" valign="top" colspan="1" rowspan="1">0.88</td><td align="left" valign="top" colspan="1" rowspan="1">0.81</td><td align="left" valign="top" colspan="1" rowspan="1">0.95</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Trans-ceftibuten<sup><xref rid="T3_FN7" ref-type="table-fn"><italic toggle="yes">g</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">1.319</td><td align="left" valign="top" colspan="1" rowspan="1">1.552</td><td align="left" valign="top" colspan="1" rowspan="1">0.85</td><td align="left" valign="top" colspan="1" rowspan="1">0.77</td><td align="left" valign="top" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>inf</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">8.946</td><td align="left" valign="top" colspan="1" rowspan="1">10.40</td><td align="left" valign="top" colspan="1" rowspan="1">0.86</td><td align="left" valign="top" colspan="1" rowspan="1">0.79</td><td align="left" valign="top" colspan="1" rowspan="1">0.93</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Data are from study VNRX-7145-102.</p></fn><fn id="T3_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>LS, least-squares.</p></fn><fn id="T3_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>Units are for geometric LS means, and do not apply to the ratios or corresponding 90% CIs.</p></fn><fn id="T3_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>AUCinf, area under the concentration-time curve from time zero to infinity; Cmax, maximum concentration.</p></fn><fn id="T3_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>CI, confidence interval.</p></fn><fn id="T3_FN6"><label>
<sup>
<italic toggle="yes">f</italic>
</sup>
</label><p>For ledaborbactam and ledaborbactam etzadroxil, test product was a single dose of CTB 400 mg + LED-E 500 mg; reference product was a single dose of LED-E 500 mg. The analysis of variance model included fixed effects for treatment, period, and sequence and a random effect for participant within sequence. An absence of interaction was indicated by a 90% CI contained within an equivalence margin of 0.80 to 1.25.</p></fn><fn id="T3_FN7"><label>
<sup>
<italic toggle="yes">g</italic>
</sup>
</label><p>For ceftibuten, test product was a single dose of CTB 400 mg + LED-E 500 mg; reference product was CTB 400 mg. The analysis of variance model included fixed effects for treatment, period, and sequence and a random effect for participant within sequence. An absence of interaction was indicated by a 90% CI contained within an equivalence margin of 0.80 to 1.25.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3-1-2"><title>Urine results</title><p>Urine samples were analyzed following single doses of LED-E 300 to 1,000 mg (<xref rid="SuF1" ref-type="supplementary-material">Table S2</xref>). For concentrations of LED and LED-E, the total amount excreted during the 48-h post-dose period (Ae<sub>0-48</sub>) increased with increasing dose, from a geometric mean of 131 to 515 mg for LED. Minimal amounts of LED-E (0.006 to 0.05 mg) were excreted in urine. The fraction of total derived material (LED-E +LED equivalent) excreted during the 48-h post-dose period ranged from 65% to 81% and was comprised almost entirely of unchanged LED. Renal clearance (CLr) of LED was similar across dose groups.</p></sec></sec></sec><sec id="s2-4"><title>Multiple doses of LED-E</title><sec id="s2-4-1"><title>Plasma results</title><p>Pharmacokinetic parameters were assessed following 10 days of dosing with LED-E 75 to 500 mg q8h. Arithmetic mean plasma concentration-time profiles for LED on Day 10 are shown in <xref rid="F1" ref-type="fig">Fig. 1B</xref>. On Day 10, LED concentrations increased rapidly after administration, reaching <italic toggle="yes">C</italic><sub>max</sub> at 0.75 to 1.50 h post-dose (<xref rid="T4" ref-type="table">Table 4</xref>). LED exposure increased less than dose proportionally, with geometric mean AUC<sub>tau</sub> (0 to 8 h post-dose) of 13.900 h&#183;&#181;g/mL (LED-E 75 mg q8h) to 69.988 h&#183;&#181;g/mL (LED-E 500 mg). For all dose levels assessed, AUC<sub>tau</sub> and <italic toggle="yes">C</italic><sub>max</sub> increased approximately 30% to 35% from the first to last dose. Day 10 <italic toggle="yes">t</italic><sub>1/2</sub> was 9.3 to 12.5 h across dose groups. Steady-state LED plasma concentrations appeared to be reached by Day 3.</p><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>Plasma pharmacokinetic parameters for ledaborbactam and ledaborbactam etzadroxil on dosing Day 10 following multiple doses of ledaborbactam etzadroxil (LED-E)<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Parameter<sup><xref rid="T4_FN2" ref-type="table-fn"><italic toggle="yes">b</italic></xref></sup></th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 75 mg q8h<sup><xref rid="T4_FN3" ref-type="table-fn"><italic toggle="yes">c</italic></xref></sup> (<italic toggle="yes">n</italic> = 9)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 150 mg q8h<xref rid="T4_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref> (<italic toggle="yes">n</italic> = 8)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 300 mg q8h<xref rid="T4_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref> (<italic toggle="yes">n</italic> = 8)</th><th align="left" valign="top" colspan="1" rowspan="1">LED-E 500 mg q8h<xref rid="T4_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref> (<italic toggle="yes">n</italic> = 9)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Ledaborbactam</td><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">T</italic><sub>max</sub>, h<sup><xref rid="T4_FN4" ref-type="table-fn"><italic toggle="yes">d</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1">1.00 (0.50&#8211;1.75)</td><td align="left" valign="top" colspan="1" rowspan="1">0.75 (0.75&#8211;1.75)</td><td align="left" valign="top" colspan="1" rowspan="1">1.13 (0.75&#8211;1.75)</td><td align="left" valign="top" colspan="1" rowspan="1">1.50 (0.75&#8211;3.00)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">3.690 (25.5)</td><td align="left" valign="top" colspan="1" rowspan="1">5.870 (11.4)</td><td align="left" valign="top" colspan="1" rowspan="1">11.600 (31.9)</td><td align="left" valign="top" colspan="1" rowspan="1">15.788 (29.9)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;AUC<sub>tau</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">13.900 (16.8)</td><td align="left" valign="top" colspan="1" rowspan="1">20.800 (15.6)</td><td align="left" valign="top" colspan="1" rowspan="1">40.900 (13.7)</td><td align="left" valign="top" colspan="1" rowspan="1">69.988 (26.4)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">t</italic><sub>1/2</sub>, h</td><td align="left" valign="top" colspan="1" rowspan="1">9.3 (8.5)</td><td align="left" valign="top" colspan="1" rowspan="1">11.4 (25.0)</td><td align="left" valign="top" colspan="1" rowspan="1">11.3 (10.4)</td><td align="left" valign="top" colspan="1" rowspan="1">12.5 (6.5)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Rac (AUC<sub>tau</sub>)</td><td align="left" valign="top" colspan="1" rowspan="1">1.32 (15.8)</td><td align="left" valign="top" colspan="1" rowspan="1">1.21 (6.96)</td><td align="left" valign="top" colspan="1" rowspan="1">1.30 (7.54)</td><td align="left" valign="top" colspan="1" rowspan="1">1.35 (16.7)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Ledaborbactam etzadroxil</td><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">T</italic><sub>max</sub>, h<xref rid="T4_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.50 (0.50&#8211;0.75)</td><td align="left" valign="top" colspan="1" rowspan="1">0.50 (0.25&#8211;0.75)</td><td align="left" valign="top" colspan="1" rowspan="1">0.50 (0.25&#8211;0.75)</td><td align="left" valign="top" colspan="1" rowspan="1">0.75 (0.50&#8211;1.50)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">C</italic><sub>max</sub>, &#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">0.122 (121)</td><td align="left" valign="top" colspan="1" rowspan="1">0.447 (100)</td><td align="left" valign="top" colspan="1" rowspan="1">0.629 (103)</td><td align="left" valign="top" colspan="1" rowspan="1">0.919 (51.6)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;AUC<sub>tau</sub>, h&#183;&#181;g/mL</td><td align="left" valign="top" colspan="1" rowspan="1">0.0855 (88.1)</td><td align="left" valign="top" colspan="1" rowspan="1">0.309 (72.9)</td><td align="left" valign="top" colspan="1" rowspan="1">0.480 (61.7)</td><td align="left" valign="top" colspan="1" rowspan="1">1.048 (37.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;<italic toggle="yes">t</italic><sub>1/2</sub>, h</td><td align="left" valign="top" colspan="1" rowspan="1">3.07 (23.8)</td><td align="left" valign="top" colspan="1" rowspan="1">4.78 (23.4)</td><td align="left" valign="top" colspan="1" rowspan="1">6.75 (18.5)</td><td align="left" valign="top" colspan="1" rowspan="1">9.14 (28.1)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;Rac (AUC<sub>tau</sub>)</td><td align="left" valign="top" colspan="1" rowspan="1">1.08 (39.7)</td><td align="left" valign="top" colspan="1" rowspan="1">1.20 (37.4)</td><td align="left" valign="top" colspan="1" rowspan="1">0.92 (41.1)</td><td align="left" valign="top" colspan="1" rowspan="1">1.07 (30.4)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;CL<sub>SS</sub>/F, L/h</td><td align="left" valign="top" colspan="1" rowspan="1">877 (88.1)</td><td align="left" valign="top" colspan="1" rowspan="1">486 (72.9)</td><td align="left" valign="top" colspan="1" rowspan="1">625 (61.7)</td><td align="left" valign="top" colspan="1" rowspan="1">477 (37.0)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#8195;V<sub>z</sub>/F, L</td><td align="left" valign="top" colspan="1" rowspan="1">3880 (70.7)</td><td align="left" valign="top" colspan="1" rowspan="1">3350 (54.1)</td><td align="left" valign="top" colspan="1" rowspan="1">6080 (65.0)</td><td align="left" valign="top" colspan="1" rowspan="1">6289 (31.0)</td></tr></tbody></table><table-wrap-foot><fn id="T4_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Except where indicated, data are geometric mean (coefficient of variation, %). Data include participants from studies VNRX-7145-101 and VNRX-7145-102.</p></fn><fn id="T4_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>AUCtau, area under the concentration-time curve through the last quantifiable concentration; CLSS/F, apparent total clearance at steady state after oral administration; Cmax, maximum concentration; Rac, accumulation ratio; Tmax, time of maximum concentration; Vz/F, volume of distribution in the terminal phase.</p></fn><fn id="T4_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>q8h, every 8 h.</p></fn><fn id="T4_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>Data are median hours (range).</p></fn></table-wrap-foot></table-wrap><p>Plasma concentrations of LED-E also increased rapidly following multiple doses of LED-E 75 to 500 mg q8h. Exposure increased with increasing dose, from a geometric mean AUC<sub>tau</sub> of 0.0855 h&#183;&#181;g/mL (LED-E 75 mg q8h) to 1.048 h&#183;&#181;g/mL (LED-E 500 mg q8h). Geometric mean <italic toggle="yes">C</italic><sub>max</sub> reached 0.5 to 0.75 h post-dose on Day 10 and increased from 0.122 &#181;g/mL (LED-E 75 mg q8h) to 0.919 &#181;g/mL (LED-E 500 mg q8h). The geometric mean <italic toggle="yes">t</italic><sub>1/2</sub> increased with dose, from 3.07 h (LED-E 75 mg q8h) to 9.14 h (LED-E 500 mg q8h).</p><p>On Day 10 following multiple doses of CTB + LED, the geometric mean LED AUC<sub>tau</sub> increased 24%&#8211;26% from the first to the last dose (<xref rid="SuF1" ref-type="supplementary-material">Table S3</xref>). In both dose groups, the LED-E geometric mean AUC<sub>tau</sub> was unchanged from the first to last dose. The geometric mean AUC<sub>tau</sub> for cis-CTB increased 44% to 52% from the first to last dose. The geometric mean AUC<sub>tau</sub> for trans-CTB increased 64% to 75% from the first to the last dose.</p></sec><sec id="s2-4-2"><title>Urine results</title><p>Ae<sub>0&#8211;48</sub> for LED increased with increasing dose, from a geometric mean of 51.6 mg (LED-E 75 mg q8h) to 345 mg (LED-E 500 q8h), and from below the limit of quantification (LED-E 75 mg q8h) to 0.03 mg (LED-E 500 mg q8h) for LED-E (<xref rid="SuF1" ref-type="supplementary-material">Table S2</xref>). Renal CLr of LED increased with increasing dose; renal CLr of LED-E was low and generally similar across dose groups. At steady state in the LED-E 500 mg q8h cohort, urinary excretion of LED-E-derived material (i.e., unchanged LED) was 84.4% over the 8-h dosing interval.</p><p>On Day 10, for both the CTB 400 mg +LED E 300 mg q8h and CTB 400 mg +LED E 500 mg q8h dose groups, the geometric mean Fe<sub>0-8</sub> of total derived material (LED-E +LED equivalent) was 72% to 77% of the last dose, with low levels of unchanged LED-E excretion. The geometric mean Fe<sub>0-8</sub> of LED-E recovered in urine was less than 0.01% of the last dose (<xref rid="SuF1" ref-type="supplementary-material">Table S4</xref>). The mean urinary Fe<sub>0-8</sub> of cis-CTB was 50% to 68% of the last dose, and the mean Fe<sub>0-8</sub> of trans-CTB was 20% to 23% of the last dose.</p></sec></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>LED-E, an oral prodrug of the active &#946;-lactamase inhibitor LED, is being developed as part of an oral combination with CTB, a third-generation cephalosporin, to address the need for effective oral options to treat complicated urinary tract infections (cUTIs) and pyelonephritis caused by drug-resistant Enterobacterales (<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">&#8211;</xref><xref rid="B9" ref-type="bibr">9</xref>). CTB + LED has demonstrated potent <italic toggle="yes">in vitro</italic> activity against drug-resistant Enterobacterales, including strains producing ESBLs, AmpC, and serine carbapenemases such as KPC and OXA-48. LED at a fixed concentration of 4 &#8201;&#181;g/mL restores CTB susceptibility, reducing MIC values by 32- to 1,024-fold, depending on the &#946;-lactamase type, with potentiated MIC<sub>90</sub> values ranging from &#8804;0.25 to &#8804;2 &#181;g/mL (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). <italic toggle="yes">In vitro</italic> studies have demonstrated that more than 98% of ESBL-positive isolates were inhibited at MICs &#8804; 1 &#181;g/mL, and the combination showed significant activity against KPC (85.9%) and OXA-48 (82.9%) producers (<xref rid="B7" ref-type="bibr">7</xref>). At ceftibuten breakpoints of &#8804;1 mg/L (EUCAST), 92.5% of 200 carbapenem-resistant <italic toggle="yes">K. pneumoniae</italic> isolates were inhibited by ceftibuten-ledaborbactam compared with only 4.5% for ceftibuten alone (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>LED-E was well tolerated at all dose levels evaluated when dosed alone or in combination with CTB, with no serious or severe TEAEs following single or multiple doses. Gastrointestinal symptoms were the most common system organ class TEAEs reported for the active intervention groups. All gastrointestinal symptoms were mild and did not result in treatment discontinuation.</p><p>Pharmacokinetic analysis of single doses of LED-E revealed a dose-proportional increase in plasma levels (as defined in the pharmacokinetic analysis section) of LED as the LED-E dose increased from 100 to 1,000 mg. LED exposure increased less than proportional to dose following 10 days of q8h dosing. Steady-state plasma concentrations were reached by Day 3, and AUC<sub>tau</sub> increased approximately 30% to 35% from the first to last doses, indicating moderate accumulation of LED in plasma after 10 days of dosing. The low plasma exposure of LED-E (&lt;2%) relative to LED exposure confirmed extensive conversion to the active &#946;-lactamase inhibitor. The increase in LED half-life with dose may be an artifact resulting from plasma concentrations falling below the assay LLOQ before reaching the terminal phase at lower doses. Urinary excretion, almost entirely as unchanged LED, is the primary route of elimination following oral dosing of LED-E (84% of the drug was excreted in urine following 500 mg q8h dosing), supporting its potential role in the treatment of cUTI. These results indicate that dose adjustments will be required for both ceftibuten (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>) and ledaborbactam etzadroxil with increasing renal impairment and that LED bioavailability is at least 68%.</p><p>The amount of unchanged LED excreted into the urine over the dosing interval at steady state (<xref rid="SuF1" ref-type="supplementary-material">Table S2</xref>) following administration of LED-E doses between 300 and 500 mg results in exposures that exceed established plasma stasis targets for LED (<xref rid="B13" ref-type="bibr">13</xref>) determined in a murine thigh model or a fixed concentration of 4 &#181;g/mL used in <italic toggle="yes">in-vitro</italic> susceptibility testing and correlated with pharmacodynamic response in a murine thigh model (<xref rid="B5" ref-type="bibr">5</xref>). Although a ledaborbactam 1-log<sub>10</sub> PK-PD target magnitude was not achievable in the murine thigh model, a humanized ceftibuten-ledaborbactam dose reduced colony counts in kidney and bladder by 3&#8211;6 log<sub>10</sub> compared to saline dosed controls in a murine cUTI model (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>Plasma pharmacokinetics results were similar between cohorts that received multiple doses of the CTB + LED E combination (<xref rid="SuF1" ref-type="supplementary-material">Table S3</xref>) and those that received LED-E alone (<xref rid="T4" ref-type="table">Table 4</xref>). Co-administration of a single dose of CTB 400 mg with LED-E 500 mg demonstrated a lack of interaction for LED and cis-CTB AUC,<sub>inf</sub> which are considered to be most closely associated with efficacy. <italic toggle="yes">C</italic><sub>max</sub> was the same or lower following coadministration for LED, LED-E, and both CTB isomers, suggesting no additional safety risk with coadministration. These results support the conclusion that there was no clinically meaningful pharmacokinetic interaction following coadministration of LED-E and CTB.</p><p>The findings from these 2 Phase 1 studies support the continued development of CTB + LED-E as a carbapenem-sparing therapeutic option for treating cUTIs and other serious infections caused by drug-resistant Enterobacterales. An effective oral combination has the potential to reduce the need for intravenous therapies, hospitalization, and healthcare costs (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>). The overall safety profile of the CTB + LED-E combination was consistent with what has been observed with CTB alone (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>), and the pharmacokinetic profile of LED is favorable for co-administration with CTB.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4-1"><title>Study design</title><p>VNRX-7145-101 was a two-part randomized, double-blind, placebo-controlled, sequential-group study of the safety and pharmacokinetics of single ascending doses (SAD, Part 1) and multiple ascending doses (MAD, Part 2) of LED-E in 48 healthy adults. In Part 1, participants in each cohort were randomized in a 3:1 ratio to receive a single dose of LED-E (100, 200, 300, 500, 800, or 1,000 mg) or placebo. In Part 2, participants in each cohort were randomized in a 3:1 ratio to receive multiple doses of LED-E (75, 150, or 300 mg) or placebo q8h for 10 days. Cohort 3 (300 mg q8h) was designed to enroll 12 participants, but enrollment was halted at 11 participants due to slow enrollment at the clinical site.</p><p>VNRX-7145-102 was a three-part randomized study of CTB and LED-E in healthy adults. Part 1 used an open-label, cross-over design to evaluate safety and drug-drug interaction (DDI) of a single dose of LED-E 500 mg, CTB 400 mg, and CTB + LED-E combination in 18 participants randomized to a dosing sequence in a 1:1:1:1:1:1 ratio. Part 2 evaluated multiple doses of LED-E 500 mg or placebo q8h, administered for 10 days, in 12 participants randomized in a 3:1 ratio. Part 3 used a double-blind, parallel-group design to evaluate safety and pharmacokinetics of CTB 400 mg + LED-E 300 mg, CTB 400 mg + LED-E 500 mg, or placebo q8h for 10 days, in 24 participants randomized in a 5:5:2 ratio. Part 3 was designed to enroll 24 participants, but enrollment was halted at 23 participants due to slow enrollment at the clinical site.</p><p>The study protocols were reviewed and approved by an institutional review board. Both studies were done in accordance with the ethical principles that have their origin in the Declaration of Helsinki, with International Council for Harmonization Guideline for Good Clinical Practice, and with all applicable regulatory requirements. All participants provided written informed consent before any screening procedures were performed. The studies were registered on ClinicalTrials.gov (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04243863" ext-link-type="uri">NCT04243863</ext-link> and <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04877379" ext-link-type="uri">NCT04877379</ext-link>).</p></sec><sec id="s4-2"><title>Participants</title><p>The studies enrolled healthy men and women ages 18 to 45 years (VNRX-7145-101) or 18 to 55 years (VNRX-7145-102) with body mass index &#8805;18.5 and &#8804;32.0 kg/m<sup>2</sup> and normal vital signs and clinical laboratory values at screening and Day &#8211;1. Participants were required to abstain from alcohol, caffeine, and xanthine-containing products beginning &#8805;2 days before admission to the research site through discharge. Key exclusion criteria were presence of a chronic condition; history of drug allergy including hypersensitivity to cephalosporins, penicillins, or &#946;-lactam antibiotics (VNRX-7145-102 only); positive drug screen; confirmed or suspected COVID-19 infection (VNRX-7145-102 only); or positive screening tests for hepatitis B surface antigen, anti-hepatitis C virus antibodies, or anti-human immunodeficiency virus 1 or 2 antibodies. Participants were required to discontinue any medications, vitamins, supplements, nicotine, and vaping products at least 14 days before Day &#8211;1; exceptions were acetaminophen at doses &#8804; 2 g/day (VNRX-7145-101) or &#8804;3 g/day (VNRX-7145-102) and hormonal contraceptives.</p></sec><sec id="s4-3"><title>Assessments</title><p>In both studies, safety analyses included all participants in both VNRX-7145-101 and VNRX-7145-102 who received at least one dose of study medication. Safety was assessed via ongoing monitoring of adverse events, symptom-directed physical examinations, and changes in clinical laboratory measures, vital signs, and ECGs.</p><p>For determination of single-dose and steady-state plasma pharmacokinetics, serial blood samples were collected at the following timepoints in VNRX-7145-101: in the SAD (Part 1), pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 h post-dose; in the MAD (Part 2), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, h after the Day 1 dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 h after the Day 10 dose, and pre-dose on Days 1&#8722;5 and 10. Serial blood samples were collected at the following timepoints in VNRX-7145-102: in Part 1 (dosing on Days 1, 5, and 9), predose and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, and 48 h postdose; in Part 2, predose on Days 1-5 and Day 10, and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, and 8 h after the first dose on Day 1 and the Day 10 dose, and 12, 16, 24, and 48 h after the Day 10 dose; in Part 3, predose and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, and 8 h after the Day 1 and 10 dose and 12, 16, 24, and 48 h after the Day 10 dose.</p><p>In VNRX-7145-101, urine samples for pharmacokinetic analysis were collected predose and at 0 to 4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48 h after single doses and on Day 10 following the last dose. Urine samples were collected in Parts 2 and 3 of VNRX-7145-102 at the following times: predose on Days 1 and 10 and at 0 to 4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48 h after the Day 10 dose.</p><p>Plasma and urine pharmacokinetics samples were assayed for LED-E, LED, and CTB, as appropriate using validated bioanalytical methods. Liquid chromatography&#8211;tandem mass spectrometry (LC-MS/MS) was used to analyze human acidified sodium fluoride potassium oxalate plasma samples for LED-E and LED using a calibration standard of 0.500 to 500 ng/mL (LED-E) and 10.0 to 10,000 ng/mL (LED) based on the analysis of 0.100 mL of acidified plasma. Quantitation used separate weighted 1 /x<sup>2</sup> linear least-squares regression analyses generated from calibration standards. Exploratory screening for metabolites was performed for some samples.</p></sec><sec id="s4-4"><title>Pharmacokinetic and statistical analyses</title><p>For VNRX-7145-101, individual concentration-time data were summarized by cohort using descriptive statistics for all participants who received at least one dose of the study treatment and provided at least one evaluable plasma concentration. Single-dose plasma pharmacokinetic parameters were determined in Part 1, and both single-dose (Day 1) and multiple-dose (Day 12) parameters were determined in Part 2. Calculation of &#955;<sub>Z</sub> was based on best fit of concentrations in the observed terminal elimination phase of a profile, and statistical inclusion of any parameter based on &#955;<sub>Z</sub> required the adjusted goodness-of-fit statistic (R<sup>2</sup><sub>adj</sub>) to be 0.8 or higher. Dose proportionality was analyzed using a power model in which pharmacokinetic exposure parameters and dose were converted to the natural log and linear regression results were reported, with the slope as the power estimate (<xref rid="B15" ref-type="bibr">15</xref>). If the 90% CI for the slope contained 1, then the hypothesis of dose proportionality for AUC or <italic toggle="yes">C</italic><sub>max</sub> could not be rejected. In Part 2, achievement of steady-state concentrations was assessed using Tukey&#8217;s multiple comparison test for pre-dose and all dosing days (Days 2 to 10) for each dose level separately.</p><p>For VNRX-7145-102, descriptive statistics was used to summarize plasma concentrations by study part and treatment at each assessment time point for all participants who received at least 1 dose of study drug and had at least one evaluable post-dose concentration measurement. Plasma pharmacokinetic parameters were calculated using noncompartmental analysis of the plasma and urine concentration-time data. In Part 1, the effect of coadministration of CTB + LED-E on LED-E, LED, cis-CTB, and trans-CTB plasma pharmacokinetic parameters was assessed. AUC<sub>inf</sub> and <italic toggle="yes">C</italic><sub>max</sub> were natural log-transformed before analysis, using a linear mixed effects model. The analysis of variance (ANOVA) model included fixed effects for treatment, period, and sequence and a random effect for participant within sequence. Point estimates, geometric means, geometric mean ratios, and corresponding 90% CIs were calculated. An absence of interaction was indicated by a 90% CI that was contained within 0.80 to 1.25.</p><p>In both studies, plasma pharmacokinetic parameters were calculated using WinNonlin (Certara; Radnor, PA), and urine pharmacokinetic parameters were calculated using SAS (SAS Institute; Cary, NC).</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank the subjects for their participation in the trial. Autumn Kelly and Donna Simcoe of Simcoe Consultants Inc. provided writing assistance based on author guidance. Lindsay Avery assisted in the production of the manuscript figures.</p><p>The study reported herein was funded by Venatorx Pharmaceuticals, Inc., and in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C.</p><p>C.F.O. : Data curation, Formal analysis, Project administration, Supervision, Visualization, Writing &#8211; original draft, Writing &#8211; review and editing; M.B.D. : Data curation, Formal analysis, Project administration, Supervision, Visualization, Writing &#8211; review and editing; J.W. : Investigation, Supervision, Writing &#8211; review and editing; K.L. : Data curation, Project administration, Supervision, Writing &#8211; review and editing; P.S. : Data curation, Formal analysis, Methodology, Supervision, Writing &#8211; review and editing; G.W. : Visualization, Writing &#8211; original draft, Writing &#8211; review and editing; H.C. : Formal analysis, Visualization, Writing &#8211; review and editing; P.M. : Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Supervision, Visualization, Writing &#8211; original draft, Writing &#8211; review and editing. All authors reviewed the manuscript, approved the final version, and agreed to be accountable for all aspects of the work.</p></ack><sec sec-type="ethics" id="s5-1"><title>ETHICS APPROVAL</title><p>The VNRX-7145-101 clinical study protocol, informed consent forms, and other study documents were reviewed and approved by an institutional review board (IRB), IntegReview IRB (Austin, Texas, USA). The VNRX-7145-102 clinical study protocol, informed consent forms, and other study documents were reviewed and approved by the Independent Ethics Committee (IEC of the foundation &#8220;Beoordeling Ethiek Biomedisch Onderzoek&#8221; (English translation: &#8220;Evaluation of Ethics in Biomedical Research&#8221;) (Doctor Nassaulaan 10, 9401 HK Assen, The Netherlands).</p></sec><sec sec-type="supplementary-material" id="s5-2"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/aac.00210-25" ext-link-type="uri">https://doi.org/10.1128/aac.00210-25</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.00210-25.SuF1</object-id><label>Supplemental tables</label><caption><title>aac.00210-25-s0001.docx</title><p>Tables S1 to S5.</p></caption><media xlink:href="aac.00210-25-s0001.docx" position="float" orientation="portrait"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murray</surname><given-names>CJL</given-names></string-name>, <string-name name-style="western"><surname>Ikuta</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Sharara</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Swetschinski</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Robles Aguilar</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bisignano</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wool</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2022</year>. <article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>The Lancet</source><volume>399</volume>:<fpage>629</fpage>&#8211;<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id><pub-id pub-id-type="pmid">35065702</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group>. <year>2024</year>. <source>WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance</source><italic toggle="yes">.</italic><publisher-name>World Health Organization</publisher-name>, <publisher-loc>Geneva</publisher-loc>.</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gauba</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>KM</given-names></string-name></person-group>. <year>2023</year>. <article-title>Evaluation of antibiotic resistance mechanisms in gram-negative bacteria</article-title>. <source>Antibiotics (Basel)</source><volume>12</volume>:<elocation-id>1590</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics12111590</pub-id><pub-id pub-id-type="pmid">37998792</pub-id><pub-id pub-id-type="pmcid">PMC10668847</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kadri</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Adjemian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Spaulding</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Ricotta</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Prevots</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Palmore</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Klompas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dekker</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Powers</surname><given-names>JH</given-names><suffix>III</suffix></string-name>, <string-name name-style="western"><surname>Suffredini</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Hooper</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Fridkin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Danner</surname><given-names>RL</given-names></string-name>, <collab>National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH&#8211;ARORI)</collab></person-group>. <year>2018</year>. <article-title>Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents</article-title>. <source>Clin Infect Dis</source><volume>67</volume>:<fpage>1803</fpage>&#8211;<lpage>1814</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciy378</pub-id><pub-id pub-id-type="pmid">30052813</pub-id><pub-id pub-id-type="pmcid">PMC6260171</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chatwin</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Hamrick</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Trout</surname><given-names>REL</given-names></string-name>, <string-name name-style="western"><surname>Myers</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Cusick</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Pulse</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Xerri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Moeck</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Daigle</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>John</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Uehara</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pevear</surname><given-names>DC</given-names></string-name></person-group>. <year>2021</year>. <article-title>Microbiological characterization of VNRX-5236, a broad-spectrum &#946;-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended-spectrum &#946;-lactamases and serine carbapenemases</article-title>. <source>Antimicrob Agents Chemother</source><volume>65</volume>:<elocation-id>e0055221</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00552-21</pub-id><pub-id pub-id-type="pmid">34001510</pub-id><pub-id pub-id-type="pmcid">PMC8284453</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karlowsky</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hackel</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sahm</surname><given-names>DF</given-names></string-name></person-group>. <year>2022</year>. <article-title>In vitro activity of ceftibuten/VNRX-5236 against urinary tract infection isolates of antimicrobial-resistant Enterobacterales</article-title>. <source>Antimicrob Agents Chemother</source><volume>66</volume>:<elocation-id>e0130421</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01304-21</pub-id><pub-id pub-id-type="pmid">34662183</pub-id><pub-id pub-id-type="pmcid">PMC8765315</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karlowsky</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wise</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Hackel</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Pevear</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Moeck</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sahm</surname><given-names>DF</given-names></string-name></person-group>. <year>2022</year>. <article-title>Ceftibuten-ledaborbactam activity against multidrug-resistant and extended-spectrum-beta-lactamase-positive clinical isolates of Enterobacterales from a 2018-2020 global surveillance collection</article-title>. <source>Antimicrob Agents Chemother</source><volume>66</volume>:<elocation-id>e0093422</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/aac.00934-22</pub-id><pub-id pub-id-type="pmid">36286518</pub-id><pub-id pub-id-type="pmcid">PMC9664860</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mendes</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Rhomberg</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Watters</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Castanheira</surname><given-names>M</given-names></string-name></person-group>. <year>2022</year>. <article-title>In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized &#946;-lactamase genes</article-title>. <source>J Antimicrob Chemother</source><volume>77</volume>:<fpage>689</fpage>&#8211;<lpage>694</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkab425</pub-id><pub-id pub-id-type="pmid">34849977</pub-id><pub-id pub-id-type="pmcid">PMC8865001</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trout</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Zulli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mesaros</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Boyd</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hamrick</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Daigle</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chatwin</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Moeck</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xerri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>CJ</given-names></string-name></person-group>. <year>2021</year>. <article-title>Discovery of VNRX-7145 (VNRX-5236 etzadroxil): an orally bioavailable beta-lactamase inhibitor for enterobacterales expressing Ambler class A, C, and D enzymes</article-title>. <source>J Med Chem</source><volume>64</volume>:<fpage>10155</fpage>&#8211;<lpage>10166</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00437</pub-id><pub-id pub-id-type="pmid">34191513</pub-id><pub-id pub-id-type="pmcid">PMC8311649</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jacobs</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Good</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Abdelhamed</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Mack</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Bethel</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Hujer</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hujer</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>van Duin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></string-name>, <string-name name-style="western"><surname>Rhoads</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Six</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Moeck</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Uehara</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Papp-Wallace</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Bonomo</surname><given-names>RA</given-names></string-name></person-group>. <year>2024</year>. <article-title>ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate &#946;-lactamase inhibitor ledaborbactam combined with ceftibuten</article-title>. <source>Antimicrob Agents Chemother</source><volume>68</volume>:<elocation-id>e0112724</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/aac.01127-24</pub-id><pub-id pub-id-type="pmid">39475259</pub-id><pub-id pub-id-type="pmcid">PMC11619242</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>ISOCEF (ceftibuten) [summary of product characteristics]</collab></person-group>. <year>2007</year>. <publisher-loc>Milan, Italy</publisher-loc><publisher-name>RECORDATI Industria Chimica e Farmaceutica S.p.A</publisher-name></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>CEDAX (ceftibuten) [product information]</collab></person-group>. <year>2010</year>. <article-title>Pernix Therapeutics, LLC, Gonzales, LA</article-title></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fratoni</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Avery</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Nicolau</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Asempa</surname><given-names>TE</given-names></string-name></person-group>. <year>2023</year>. <article-title>In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral &#946;-lactam/&#946;-lactamase inhibitor combination</article-title> . <source>Antimicrob Agents Chemother</source><volume>78</volume>:<fpage>93</fpage>&#8211;<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkac359</pub-id><pub-id pub-id-type="pmcid">PMC10205465</pub-id><pub-id pub-id-type="pmid">36272135</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="report"><person-group person-group-type="author"><string-name name-style="western"><surname>Asempa</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>K&#246;nig</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nicolau</surname><given-names>DP</given-names></string-name></person-group>. <year>2025</year>. <article-title>In vivo efficacy of ceftibuten-ledaborbactamhuman-simulated oral exposures against ESBL-and carbapenemase producing Enterobacterales in the murine urinary tract infection model (UTI)</article-title>. <source>American Society for Microbiology Microbe</source></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Vandenhende</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>DeSante</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Farid</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Welch</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Callaghan</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Forgue</surname><given-names>ST</given-names></string-name></person-group>. <year>2000</year>. <article-title>Confidence interval criteria for assessment of dose proportionality</article-title>. <source>Pharm Res</source><volume>17</volume>:<fpage>1278</fpage>&#8211;<lpage>1283</lpage>. doi:<pub-id pub-id-type="doi">10.1023/a:1026451721686</pub-id><pub-id pub-id-type="pmid">11145235</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>